Found 53 matching trials
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself. N/A A retrospective study of de-identified (to preserve patient privacy) patien...
Show More Learn More & Join Trial
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer N/A This is a multi-center biomarkers study aiming to prospectively collect bio...
Show More Location
Hospital Santo Stefano
Learn More & Join Trial
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer PHASE2 This research study is evaluating a drug called Palbociclib in combination ...
Show More Location
University of California, San Francisco
Learn More & Join Trial
Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer PHASE3 This study is a prospective, open-label, multicenter, randomized controlled...
Show More Location
Multiple Locations
Learn More & Join Trial
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region N/A retrospective non-interventional study (NIS) that aims to describe the demo...
Show More Location
Hamad Medical Corporation
Learn More & Join Trial
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark. N/A The purpose of this study is to describe the effect of the medicine palboci...
Show More Location
Copenhagen University Hospital, Rigshospitalet
Learn More & Join Trial
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer PHASE3 POLAR is a phase III clinical trial, which will test the safety and efficac...
Show More Status
Active Not Recruiting
Location
Medizinische Universität Graz (MUG)
Learn More & Join Trial
European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies N/A A retrospective observational analysis of de-identified data from a multina...
Show More Location
Sankt Josef Hospital Braunau
Learn More & Join Trial
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer PHASE3 Given the uncertain benefit in efficacy of adding CDK 4/6 to first rather t...
Show More Status
Active Not Recruiting
Location
Jeroen Bosch Ziekenhuis
Learn More & Join Trial
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients NA Approximately 3.5% to 6% of newly diagnosed breast cancer patients are stag...
Show More Status
Active Not Recruiting
Location
Institut de Cancérologie de l'Ouest-Site Paul Papin
Learn More & Join Trial